Researchers complete final analysis of a phase 3 study of men with hemophilia B receiving intravenous etranacogene dezaparvovec.
Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...
Detailed price information for Taysha Gene Therapies Inc (TSHA-Q) from The Globe and Mail including charting and trades.
Scientists from the Smidt Heart Institute, Cedars-Sinai Medical Center (Los Angeles, CA, USA) recently explored ...
Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...
The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has ...
Amsbio has launched a new range of Adeno-Associated Virus (AAV) reference standards to help researchers optimise AAV ...
The FDA previously declined to approve UX111 citing CMC-related observations, but the firm is hopeful the agency will approve its new regulatory application.
Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results